CAVEI interim recommendation for the initial prioritization of groups to be vaccinated against SARS-CoV-2 in the context of limited supply

This document complements the “CAVEI Interim Statement on Target Groups of vaccinate against SARS-CoV-2 ”published on June 30, 2020, considering the progress of the clinical studies related to vaccines and increased knowledge of epidemiological analysis of the pandemic to date and an initial scenario with limited supply of doses. It also considers that the population included in the phase 3 clinical studies of the Candidate vaccines against SARS-CoV-2 are adults 18 years of age and older, healthy or with comorbidities controlled.

Given that the production of COVID-19 vaccines licensed for use will have a maximum capacity and that, consequently, the supply of vaccine to the countries will be limited in the first stage, it is necessary to prioritize access to COVID-19 vaccine among the population resident in Chile for this period. For this recommendation, the criteria applied to the prioritization of target groups to vaccinate against SARS-CoV-2 are to preserve the response health, maximize individual and collective benefits, reduce morbidity and mortality from COVID19, and restore and maintain State functions and social activities and services essential.